BeiGene slips on decision to halt lung cancer program

Image Source BeiGene (BGNE) ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program targeting its antibody therapy ociperlimab (BGB-A1217) in lung cancer in reaction to disappointing safety and efficacy data. The.